Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearbridge HealthFRA:5C6 EV-to-EBIT is -0.81 as of Sep. 12, 2026. The stock has 4 warning signs investors should review. Among 108 Medical Diagnostics & Research companies, Clearbridge Health ranks worse than 925925% on this metric.
The historical rank and industry rank for Clearbridge Health's EV-to-EBIT or its related term are showing as below:
FRA:5C6'
s EV-to-EBIT Range Over the Past 10 Years
Min: -12.16 Med: -2.01 Max: 24.16
Current: -0.79
During the past 12 years, the highest EV-to-EBIT of Clearbridge Health was 24.16. The lowest was -12.16. And the median was -2.01.
FRA:5C6's EV-to-EBIT is ranked worse than 100% of 108
companies
in the Medical Diagnostics & Research industry
Industry Median: 25.08
vs FRA:5C6: -0.79
Clearbridge Health (FRA:5C6) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Clearbridge Health's Enterprise Value for the quarter that ended in Jun. 2026 was €1.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clearbridge Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-8.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearbridge Health EV-to-EBIT Related Terms
Clearbridge Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Clearbridge Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Clearbridge Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearbridge Health EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clearbridge Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Clearbridge Health's EV-to-EBIT falls into.
Clearbridge Health's current Enterprise Value is €6.52 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clearbridge Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-8.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearbridge Health (FRA:5C6) has a EV-to-EBIT of -0.81 as of Sep. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clearbridge Health and its competitors. According to the industry distribution chart, Clearbridge Health ranks #999999 out of 108 companies in the Medical Diagnostics & Research industry.
Is Clearbridge Health's EV-to-EBIT too high?
Clearbridge Health's current EV-to-EBIT is -0.81. Based on the distribution chart, Clearbridge Health ranks #999999 out of 108 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Clearbridge Health's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clearbridge Health ranks #999999 out of 108 companies for EV-to-EBIT. This places Clearbridge Health in the lower half of its industry. The industry median EV-to-EBIT is 25.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 25.08, based on 108 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Clearbridge Health and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 25.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearbridge Health's current EV-to-EBIT is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearbridge Health stock overvalued right now?
Clearbridge Health (FRA:5C6) has a current EV-to-EBIT of -0.81. The current EV-to-EBIT is -0.81. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Clearbridge Health (FRA:5C6), the current EV-to-EBIT is -0.81 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearbridge Health Ltd provides health care services. It is an integrated healthcare group with end-to-end diagnostic abilities, deploying non-invasive tests to identify and manage illness. The segments are Strategic investments; Others ; Medical clinics; Corporate segment and Investment. It derives key revenue from the Medical clinics segment. The medical clinics/centres segment involves the provision of general medical, dental and clinical services and distribution of the medical and pharmaceutical products. The group has a business presence in Singapore, Philippines, Hong Kong, Malaysia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5C6 has been successfully added to your 
